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Background. Failure to exclusively breastfeed is often caused by a perception of insufficient breastmilk supply. Galactogogues are 
frequently prescribed in these circumstances, but this is supported by sparse scientific data with safety concerns for both mother and 
infant. The exact extent of galactogogue use in South Africa (SA) is not well known.
Objectives. To assess breastfeeding behaviour, galactogogue use and perceived galactogogue side-effects among patients attending 
International Board Certified Lactation Consultant (IBCLC) private practices.
Methods. We administered a self-developed, expert-reviewed questionnaire in five IBCLC private practices within the Cape Town 
Metropole, SA. All patients attending the practices during an 8-week period were invited to participate.
Results. Data from 104 participants were included in the study. An exclusive breastfeeding rate of slightly more than 50%, associated 
with greater parity (p=0.029), was found. Perceived lack of breastmilk predicted galactogogue use (p=0.013). There was a high 
prevalence of galactogogue use (54%), with 80% of these participants using non-prescription medication. Sulpiride was the most 
common prescription medication used. Increased milk production was reported by 41% (n=23) of galactogogue users, while 30% 
(n=17) reported no effect. Most reported side-effects were minor. 
Conclusions. Prevalence of galactogogue use exceeded other published data. Sulpiride was most frequently prescribed, despite 
not being recommended during breastfeeding. A large group of participants reported poor efficacy. The effect of vaginal delivery 
and immediate skin-to-skin contact after delivery on milk production might be smaller than previously reported in mothers who 
are personally motivated to breastfeed. Healthcare practitioners should acknowledge breastfeeding mothers’ concerns regarding 
insufficient milk supply and emphasise correct breastfeeding technique. 
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Exclusive breastmilk is the optimal feeding for infants up to 6 months 
of age.[1] Breastfeeding has been associated with short-term benefits 
such as providing the child’s first immunity and reducing infant 
morbidity and mortality associated with infections.[2] Long-term 
benefits include lower mean blood pressure and total cholesterol 
in adulthood, and improved performance in intelligence tests.[2] 
However, mothers struggle to achieve exclusive breastfeeding and 
according the World Health Organization (WHO)᾽s global database 
on infant and young child feeding the rate of exclusive breastfeeding in 
South Africa (SA) is among the lowest in the world, at 11.6% in infants 
<4 months and 8.3% in infants ≤6 months of age, compared with a 
global rate of 38%.[3] There are many contributing factors leading to 
low breastfeeding rates, but the most common reason is insufficient 
breastmilk supply.[4]
Galactogogues are often prescribed to augment breastmilk supply in 
resource-rich environments.[5] Galactogogues are dopamine antagonists 
such as antipsychotics, antiemetics and natural supplements which 
enhance lactation by increasing serum prolactin.[6] Galactogogue-
mediated rise in serum prolactin may transiently increase milk 
production, but after 2 weeks postpartum it has no effect on lactational 
performance.[5,7] A recent Cochrane review concluded that the use of 
galactogogues was not associated with a significant improvement in 
longer-term outcomes of breastfeeding in preterm infants.[1] In addition, 
galactogogues have safety concerns in the mother and the infant.
The antipsychotics sulpiride and chlorpromazine cross into breast-
milk, while chlorpromazine may adversely affect the developing 
central nervous system of the infant.[4,8] In turn, mothers may 
develop movement disorders such as acute dystonic reactions.[4] 
Antiemetics exploited for their blocking of dopamine receptors 
also have safety concerns.[8] Metoclopramide is structurally related 
to the antipsychotic sulpiride and not recommended during 
breastfeeding.[8] Domperidone has been associated with an increased 
risk of QT interval prolongation and sudden cardiac death.[5] Natural 
supplements such as milk thistle and fenugreek have limited safety 
data during lactation (DRUG-REAX Database, Truven Health 
Analytics, Inc). 
Taken together, the exact extent of galactogogue use in SA is 
unknown and the awareness of the benefit-risk of galactogogue use 
by breastfeeding mothers has not been documented. The objectives 
of this study were to describe breastfeeding behaviour, assess 
galactogogue use and determine perceived efficacy and side-effects 
in breastfeeding mothers and their infants. 
Methods
The investigators developed a questionnaire based on specific 
research gaps identified in the literature, followed by review from 
relevant experts in paediatrics, neonatology and breastfeeding 
consulting. The questionnaire contained three sections. The 
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first section captured demographic information including factors 
previously shown to influence breastfeeding, such as type of delivery, 
parity and having skin-to-skin contact. It also assessed duration 
of breastfeeding, mixed feeding and reasons for not exclusively 
breastfeeding. The second section assessed galactogogue use, the 
type, duration, dose, who recommended it and what the perceived 
efficacy and duration of the effect were. The last section captured data 
regarding side-effects in the mother and infant (Table 1). According 
to the information gathered, participants were retrospectively 
classified into one of the following groups: exclusive breastfeeding, 
exclusive formula feeding, mixed feeding (breastfeeding and 
using formula milk concurrently), intermittent mixed feeding 
(exclusively breastfeeding, but who have used formula feeds in 
the past) and breastfeeding to formula feeding (mothers who are 
using only formula feeds, who in the past breastfed exclusively). 
The first day of data collection was used to pilot the questionnaire. 
No concerns were identified and the study commenced on the 
following day.
We approached the International Board Certified Lactation 
Consultants (IBCLCs) practising in the private sector in the Cape 
Town Metropole via the IBCLC᾽s communication network. A total 
of 22 had been approached and 5 IBCLCs practising in Rondebosch, 
Bellville, Stellenbosch and Somerset West, agreed to participate in 
the study. All the mothers consulting the IBCLCs during an 8-week 
period (starting 6 October 2015) irrespective of the reason for the 
consultation, were asked to participate in the study by completing 
the questionnaire. The IBCLCs avoided data duplication by keeping 
a record of each participant who had completed a questionnaire. 
Only data from participants who had signed informed consent 
and completed the questionnaire were included in the study. 
Questionnaires were excluded from the data set when, based 
on consensus by the researchers, answers were ambiguous or 
incomplete. Ethical approval was obtained from the Stellenbosch 
University Health Research Ethics Committee (ref. no. S15/04/093).  
Results
A total of 108 participants signed informed consent and completed 
the questionnaires. Data from four participants were excluded due 
to incomplete data. 
Exclusive breastfeeding in this population was achieved by slightly 
more than 50% of the participants, with a downward trend with 
increasing age of the infant. The most common reason for the use of 
formula milk was insufficient breastmilk production in the opinion 
of the participant. A statistically significant association was found 
between galactogogue use and perceived insufficient breastmilk 
supply (p=0.013). There was no statistically significant association 
between type of delivery and exclusive breastfeeding (p=0.099). A 
statistically significant increase in exclusive breastfeeding rate was 
shown in mothers with two or more children (p=0.029), compared 
with mothers with only one child. Having skin-to-skin contact 
within 1 hour of delivery was not associated with an increase in 
exclusive breastfeeding in this study (p=0.308). 
Galactogogues were used by more than half of the participants 
(54%, n=56). Counselling on breastfeeding techniques to enhance 
breastmilk production prior to using galactogogues was given to 
64% (n=36) of galactogogue users. Non-prescription medication 
was used by 80% of galactogogue users; the berry elixir-containing 
‘Jungle Juice’, for which there appeared to be no standard 
ingredients, was most widely used (52%, n=29) (Table 3). The dose 
and use of ‘Jungle Juice’ varied greatly between 250 mL and 2 L per 
day. Fenugreek was mostly used in the capsule form, at ≤3 capsules 
per day (90%, n=19). Prescription medication was used by 48% of 
galactogogue users, of which low-dose sulpiride (50 mg 2 - 3 times 
per day) was the most frequently used (Table 2). The median age of 
infants when starting sulpiride was 2 weeks, while the duration of 
sulpiride use was 4 weeks, with the interquartile range 2 - 11 weeks. 
A single galactogogue was used by almost half of the participants 
(46%, n=26), while two and three galactogogues (including both 
prescription medication and supplements) were simultaneously 
Table 1. Participant characteristics
Characteristic
Total number of 
participants, n (%)* EBF,† n (%) IMF,‡  n (%) MF,§ n (%) BF-FF ¶ n (%) EFF,|| n (%)
Participants included (N) 104 58 (56) 9 (8) 22 (21) 12 (12) 3 (3)
Type of delivery 
Caesarean section 78 (75) 40 (69) 7 (78) 22 (100) 6 (50) 3 (100)
Vaginal delivery 26 (25) 18 (31) 2 (22) - 6 (50) -
1 hour skin-to-skin contact post delivery 62 (60) 37 (64) 6 (67) 8 (36) 8 (67) 3 (100)
Live children of participants
1 69 (66) 33 (57) 9 (100) 17 (77) 8 (66) 2 (67)
2 29 (28) 22 (38) - 4 (18) 2 (17) 1 (33)
≥3 6 (6) 3 (5) - 1 (5) 2 (17) -
Galactogogue use 56 (54) 26 (45) 7 (78) 16 (73) 7 (58) -
Breastfeeding advice received before 
galactogogue use 36 (64) 12 (46) 4 (44) 13 (81) 7 (100) N/A
EBF = exclusive breastfeeding; IMF = intermittent mixed feeding; MF = mixed feeding; BF-FF = breastfeeding to formula feeding; EFF = exclusive formula feeding; N/A = not applicable.
*Unless otherwise specified.
†Mothers only breastfeeding and using no other milk supplement.
‡Defined as mothers exclusively breastfeeding, but who have used formula feeds in the past.
§Mothers breastfeeding and using formula supplementation concurrently.
¶Mothers who are using only formula feeds, who in the past breastfed exclusively.
||Defined as mothers using formula feeds only.
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used in 21% (n=12) and 12.5% (n=7) of participants, respectively. 
A subjectively judged good increase in milk production was 
reported by 41% (n=23) of the galactogogue users and 30% (n=17) 
of the group reported no effect. The majority of the users who no 
longer used a galactogogue reported that the effect lasted only 
during use (56%, n=18), or a few days after stopping (28%, n=9). 
No statistically significant associations were found between any of 
the medications used as galactogogues and the effect on breastmilk 
production, or the duration of the effect after stopping (Table 3). 
Only a few participants reported that they were counselled on 
possible side-effects (21%, n=12) before galactogogue initiation. 
Side-effects were reported in 9 mothers and 2 infants. The side-
effects were mostly associated with sulpiride, varying from 
improved emotional wellbeing (n=2) to moodiness (n=2), which 
was subjectively noted to be severe in one case. One participant also 
mentioned that sulpiride contributed to difficulty in losing weight. 
Other side-effects were associated with brewer’s yeast (cramps in 
an infant and vaginal pruritis in a mother), berry elixir (improved 
maternal energy levels) and fenugreek (increased heart rate and 
breast congestion in one mother). 
In most cases (55%, n=31), galactogogues were recommended 
by medical practitioners, with obstetricians accounting for 35% 
(n=20). Nursing practitioners and certified lactation practitioners 
recommended galactogogues in  38% (n=21) of cases. Forty-five 
percent (n=25) of galactogogue users reported a recommendation 
from friends, family or other sources. 
Discussion
Our study contributes to the limited SA data regarding breastfeeding 
behaviour, galactogogue use and perceived efficacy and side-
effects in breastfeeding mothers and their infants. We found a high 
exclusive breastfeeding rate in all age categories compared with 
the national breastfeeding rates in SA,[3] which could be explained 
by the specific population group who were seeking the advice of 
breastfeeding consultants, indicating a high level of motivation to 
breastfeed.
Successful breastfeeding has been associated with vaginal delivery, 
skin-to-skin contact in the first hour after delivery and a higher 
parity.[9,10] In our study this association was found with parity, but 
not with the type of delivery or skin-to-skin contact. Reasons for 
Table 3. Reasons for the use of formula milk (N=46)
Reason n (%)
Association of reason 
listed and the use of a 
galactogogue (p-value) IMF MF BF-FF EFF
Perception of too little breastmilk 23 (50) 0.01 4 11 7 1
Mastitis, thrush or painful breastfeeding 6 (13) 0.93 1 4 1 0
Returned to work and could not express 2 (4) 0.29 0 2 0 0
Use of alcohol, nicotine and other harmful substances 1 (2) 0.17 0 1 0 0
Use of chronic medication and recommended not to BF 1 (2) 0.17 0 0 1 0
BF found to be emotionally challenging 5 (11) 0.21 0 1 2 2
Social pressures to stop BF 0 0 0 0 0 0
Infant refused to take breastmilk 10 (22) 0.25 0 3 7 0
Medical problems/medical advice to use formula milk 17 (37) 0.22 5 9 2 1
Other 9 (20) 0.63 2 5 1 1
Table 2. Type of galactogogue used (N=56)
Type N (%) EBF IMF MF BF-FF EFF
Total galactogogue use 56 (54) 26 (46) 7 (13) 16 (29) 7 (13) -
Prescription medication 27 (48) 7 (26) 3 (11) 10 (37) 7 (26) -
Sulpiride 25 (48) 7 (28) 3 (12) 9 (36) 6 (24) -
Metoclopramide 2 (4) 0 (0) 0 (0) 1 (50) 1 (50) -
Supplements 45 (80)
Herbal (fenugreek)* 21 (47) 7 (33) 5 (24) 7 (33) 2 (10) -
Non-herbal (Jungle Juice† and Stoney‡) 33 (73) 18 (55) 4 (12) 9 (27) 2 (6) -
Miscellaneous§ 12 (27) 2 (17) 1 (8) 8 (67) 1 (8) -
*Trigonella foenum-graecum is a herb containing phyto-oestrogens, which are plant chemicals similar to oestrogen. Diosgenin is specifically implicated to increase breastmilk production.
†A tonic made with blackthorn berry elixir (50 mL), rehydration mixes (sachets containing carbohydrates, electrolytes and possibly antioxidants), fruit juice or rooibos tea (1 L) and water (2 L). Rescue 
remedy drops are sometimes added in varying quantities.
‡A ginger-flavoured carbonated drink.
§Other galactogogues include:
Brewer’s yeast – Saccharomyces cerevisiae  
Prolac –  homeopathic combination sublingual tablet to stimulate milk production (Helonias ioica, Urtica urens, Ricinus communis, calcarea carbonica, calcarea phosphorica, Vitex agnus-castus, ferrum 
phosphoricum, Pulsatilla, graphites, calcarea fluorica)
Lactogogue tea – herbal tea (can be made with the leaves of different herbal plants, although fenugreek is most commonly used)
Lactation cookies – oats-based cookie containing brewer’s yeast and flaxseed 
Protein powder – a powder containing one of three main proteins: whey, soy and casein
Oats – Avena sativa
Milk stout – stout containing lactose, often used in the fermentation of beer
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this can be attributed to the study population who, while seeking 
breastfeeding advice and assistance, also commonly make use 
of private-sector healthcare, where there is a high incidence of 
caesarean delivery. It may, therefore, also imply a smaller than 
expected role for these factors in predicting breastfeeding success 
in a motivated population. We found that galactogogues were 
frequently prescribed and used by more than half of the participants, 
which is higher than in high-income settings internationally, where 
a 5 - 33% prevalence of galactagogue use has been documented.[11,12] 
In our study, supplements were the most preferred galactogogues, 
with the use of fenugreek and berry elixir-containing juices being 
widespread, often in combination with prescription medications. 
Safety and efficacy data supporting the use of galactogogue 
supplements are limited. We found that the preferred prescription 
galactogogue was sulpiride. Internationally, domperidone is most 
frequently prescribed in high-income settings.[5]
Given the high incidence of galactogogue usage observed, it is 
noteworthy that a relatively high percentage of participants found 
no effect on breastmilk production when using galactogogues. This, 
along with the high motivation of this study group to breastfeed, 
might explain the high incidence of the use of a combination of 
galactogogues. Although an objective analysis of efficacy is limited 
by the retrospective study design, our data do not support this 
practice to improve breastfeeding performance.
Most participants used galactogogues for a number of weeks, 
and often when their infants were beyond the neonatal period. 
Galactogogues should be prescribed with care with the best scientific 
evidence available, taking into account that there is no evidence to 
support the use of a galactogogue for longer than 2 weeks,[5] and 
that after 2 weeks postpartum it has no proven effect on lactational 
performance.[5,7] In addition, infant suckling is the most important 
factor for breast milk production once lactation is established, and not 
prolactin-induced increases in breastmilk volume.[13] 
We also assessed the subjective experience of potential side- effects. 
There are very limited data regarding the safety of galactogogues. 
The side-effects described by study participants were mostly minor 
complaints and some could be seen as positive effects. Of note is the 
relatively low rate of side-effects reported, especially in infants. The 
study design is such, however, that reliable conclusions cannot be 
drawn on the safety and potential risks of these medications. 
Our study findings were limited by a number of factors, the first 
of which was the small sample size. Second, the study population 
was prone to selection bias, with only IBCLCs serving the private 
sector being included. It is likely that the clients attending these 
practices are highly motivated to breastfeed. While this allows the 
collection of data from those most likely to use galactogogues, it 
might skew the actual prevalence of galactogogue use in the general 
population. Thirdly, we cannot exclude reporting bias, given that the 
study was designed to investigate women who are highly motivated 
to breastfeed and, lastly, the study design was retrospective and 
uncontrolled. 
Future research should prospectively collect galactogogue safety 
and efficacy data given the large proportion of women found in our 
study who use galactogogues for extended periods of time.
Conclusion
This study found that galactogogues were frequently used, with 
a prevalence that exceeded other published data. We found 
that sulpiride was frequently prescribed even though it was not 
recommended during breastfeeding. Furthermore, the time of 
initiation and duration of galactogogue use was not in accordance 
with current guidelines. Doctors and other healthcare practitioners 
should acknowledge breastfeeding mothers’ concerns regarding 
insufficient milk supply, and place more emphasis on correct 
breastfeeding technique and other behavioural factors.[5] 
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